BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan
· Delayed Price · Currency is TWD 38.40
-0.70 (-1.79%)
At close: Dec 5, 2025
BioGend Therapeutics Company Description
BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products.
It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system.
The company was incorporated in 2016 and is based in Taipei, Taiwan.
BioGend Therapeutics Co., Ltd.
| Country | Taiwan |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Te-Li Chen |
Contact Details
Address: No.3-2, Park Street Taipei, 115 Taiwan | |
| Phone | 886 2 2655 8366 |
| Website | biogend.com |
Stock Details
| Ticker Symbol | 6733 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006733009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Te-Li Chen M.D., Ph.D. | Chairman and GM |
| Guifen Zhang | Senior Manager |
| Shuwei Zhao | Senior Manager |
| Bozhi Zhang | Senior Manager |
| Bowei Li | Senior Manager |